Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SHBG | P04278 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.45 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6194349 | 0.87 | CTBP2 (0.58) | CTBP2PKMNPC1RAB9ASHBG | |
| SCHEMBL31365969 | 0.87 | CTBP2 (0.58) | CTBP2PKMNPC1RAB9ASHBG | |
| SCHEMBL21100152 | 0.85 | IAPP (0.46) | CTBP2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL15178188 | 0.85 | CTBP2 (0.53) | CTBP2PKMNPC1RAB9ASHBG | |
| SCHEMBL8310690 | 0.82 | HTT (0.60) | CTBP2PKMNPC1RAB9ASHBG | |
| SCHEMBL2252410 | 0.82 | CTBP2 (0.53) | CTBP2PKMNPC1RAB9ASHBG | |
| SCHEMBL29210932 | 0.81 | GABRA1 (0.44) | NPC1RAB9ASHBGALDH1A1 | |
| SCHEMBL21851724 | 0.81 | SHBG (0.49) | CTBP2PKMNPC1RAB9ASHBG | |
| 1,2-Dichlorobenzene SCHEMBL27361510 | 0.81 | LMNA (0.50) | NPC1RAB9AALDH1A1 | |
| SCHEMBL8679305 | 0.80 | HTT (0.55) | CTBP2PKMNPC1RAB9ASHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-9206175-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206175-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206175-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-0924193-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| CN-1217186-A | Preparation method for medicinal composition containing hydrogenated pyridine derivative as active components | SANKYO CO (JP) | 1999-05-26 | — | — | CN | disclosed |
| CN-1041730-C | Process for preparing hydrogenated pyridine derivatives | SANKYO CO (JP) | 1999-01-20 | — | — | CN | disclosed |
| US-5811293-A | CULTURE PRODUCT AS CHEMICAL INTERMEDIATE FOR ANTI-OBESITY AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0542411-B1 | TETRAHYDROTHIENOPYRIDINE DERIVATIVES, FURO AND PYRROLO ANALOGS THEREOF AND THEIR PREPARATION AND USES FOR INHIBITING BLOOD PLATELET AGGREGATION | SANKYO CO (JP) | 1998-08-12 | — | — | EP | disclosed |
| US-5436242-A | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof for inhibiting blood platelet aggregation | SANKYO COMPANY, LIMITED (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0654534-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-24 | — | — | EP | disclosed |
| US-5288726-A | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation | UBE INDUSTRIES LIMITED (JP) | 1994-02-22 | — | — | US | disclosed |
| CN-1074446-A | Hydroxypyridine Derivatives | SANKYO CO (JP) | 1993-07-21 | — | — | CN | disclosed |
| EP-0542411-A2 | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation | Sankyo Company Limited (JP) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | XDH, CYP2B6, COX6B1 | CTBP2 4336/4885PKM 2536/4885NPC1 2113/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CTBP2 2470/4885PKM 3874/4885NPC1 65/4885 |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | CTBP2 4336/4885PKM 2536/4885NPC1 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.